• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why DatChat Shares Are Trading Lower By Around 33%; Here Are 20 Stocks Moving Premarket

    1/17/24 8:18:56 AM ET
    $ADAG
    $BANL
    $DATS
    $ESLA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Oil Refining/Marketing
    Energy
    Get the next $ADAG alert in real time by email

    Shares of DatChat, Inc. (NASDAQ:DATS) fell sharply in pre-market trading after announcing a proposed underwritten public offering of common stock.

    DatChat shares dipped 33.1% to $2.13 in pre-market trading

    Here are some other stocks moving in pre-market trading.

    Gainers

    • RiskOn International, Inc. (NASDAQ:ROI) shares rose 51.3% to $0.2250 in pre-market trading.
    • Meta Materials Inc. (NASDAQ:MMAT) shares jumped 33.2% to $0.0966 in pre-market trading after surging over 20% on Tuesday.
    • LQR House Inc. (NASDAQ:LQR) gained 25.2% to $2.53 in pre-market trading after dipping 45% on Tuesday. LQR House announced an increase of its share buyback program to $5 million.
    • Kintara Therapeutics, Inc. (NASDAQ:KTRA) shares climbed 19.3% to $0.1514 in pre-market trading after falling more than 9% on Tuesday.
    • Zapp Electric Vehicles Group Limited (NASDAQ:ZAPP) shares gained 15.7% to $0.2950 in pre-market trading after dipping 13% on Tuesday.
    • Solid Power, Inc. (NASDAQ:SLDP) gained 15.1% to $1.37 in pre-market trading. Solid Power deepened its partnership with SK On with three new agreements.
    • Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) surged 10.7% to $0.6599 in pre-market trading. Salarius Pharmaceuticals said that the U.S. Patent and Trademark Office has issued U.S. Patent No. 11,773,080, titled “Deuterium-enriched isoindolinonyl-azepanediones and related compounds and methods of treating medical disorders using same.”
    • Estrella Immunopharma, Inc. (NASDAQ:ESLA) gained 9.4% to $1.40 in pre-market trading after gaining around 4% on Tuesday.
    • Ocean Biomedical, Inc. (NASDAQ:OCEA) surged 9.3% to $0.63 in pre-market trading after dipping over 8% on Tuesday.
    • Natera, Inc. (NASDAQ:NTRA) gained 8.3% to $68.10 in pre-market trading. Natera announced that jury in US District Court for W. District of Texas ruled in patent infringement lawsuit brought by Ravgen, awarding $57 million in damages, below the $410 million sought.

    Losers

    • Phunware, Inc. (NASDAQ:PHUN) shares fell 58.7% to $0.1735 in pre-market trading. Phunware announced pricing of $7.0 million registered direct offering priced at-the-market under Nasdaq rules.
    • Remark Holdings, Inc. (NASDAQ:MARK) shares fell 21.4% to $0.5324 in pre-market trading after jumping around 48% on Tuesday.
    • MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) shares fell 12.4% to $0.1779 in pre-market trading. MyMD Pharmaceuticals has been granted Canadian patent number 3013634 Titled "Methods Of Increasing Hair Growth and Improving Hair Appearance."
    • Elevai Labs, Inc. (NASDAQ:ELAB) fell 12.4% to $1.21 in pre-market trading. ELEVAI Labs shares fell around 19% on Tuesday after the company announced it signed an exclusive, worldwide manufacturing and processing technology licensing agreement with INmune Bio.
    • Verb Technology Company, Inc. (NASDAQ:VERB) shares declined 10.7% to $0.1160 in pre-market trading after gaining around 3% on Tuesday.
    • Adagene Inc. (NASDAQ:ADAG) shares fell 10.3% to $3.38 in pre-market trading after the company announced interim results from masked anti-CTLA-4 SAFEbody ADG126 in combination with pembrolizumab in metastatic microsatellite-stable colorectal cancer.
    • Salem Media Group, Inc. (NASDAQ:SALM) fell 9.7% to $0.30 in pre-market trading. Salem Media, last month, announced it will voluntarily delist from the Nasdaq Global Market.
    • Rail Vision Ltd. (NASDAQ:RVSN) fell 7.7% to $1.55 in pre-market trading after gaining over 20% on Tuesday.
    • CBL International Limited (NASDAQ:BANL) fell 7.4% to $1.40 in pre-market trading after gaining around 12% on Tuesday.


    Now Read This: U.S. Bancorp, Charles Schwab And 3 Stocks To Watch Heading Into Wednesday

    Get the next $ADAG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADAG
    $BANL
    $DATS
    $ESLA

    CompanyDatePrice TargetRatingAnalyst
    Natera Inc.
    $NTRA
    4/14/2026Outperform
    William Blair
    Solid Power Inc.
    $SLDP
    3/16/2026$7.00Buy
    H.C. Wainwright
    Natera Inc.
    $NTRA
    1/7/2026$300.00Buy
    Citigroup
    Natera Inc.
    $NTRA
    12/2/2025$265.00Overweight
    Morgan Stanley
    Adagene Inc.
    $ADAG
    11/24/2025$9.00Buy
    Guggenheim
    Natera Inc.
    $NTRA
    10/27/2025$172.00Underperform → Neutral
    BNP Paribas Exane
    Natera Inc.
    $NTRA
    9/22/2025$175.00Equal Weight
    Wells Fargo
    Adagene Inc.
    $ADAG
    8/6/2025$7.00Outperform
    Leerink Partners
    More analyst ratings

    $ADAG
    $BANL
    $DATS
    $ESLA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Sheena Jonathan

    4 - Natera, Inc. (0001604821) (Issuer)

    4/21/26 9:05:05 PM ET
    $NTRA
    Medical Specialities
    Health Care

    SEC Form 3 filed by new insider Rubin Eric H

    3 - Natera, Inc. (0001604821) (Issuer)

    4/9/26 8:25:07 PM ET
    $NTRA
    Medical Specialities
    Health Care

    SEC Form 4 filed by Rabinowitz Matthew

    4 - Natera, Inc. (0001604821) (Issuer)

    4/8/26 9:05:05 PM ET
    $NTRA
    Medical Specialities
    Health Care

    $ADAG
    $BANL
    $DATS
    $ESLA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    William Blair initiated coverage on Natera

    William Blair initiated coverage of Natera with a rating of Outperform

    4/14/26 8:34:48 AM ET
    $NTRA
    Medical Specialities
    Health Care

    H.C. Wainwright initiated coverage on Solid Power with a new price target

    H.C. Wainwright initiated coverage of Solid Power with a rating of Buy and set a new price target of $7.00

    3/16/26 8:42:58 AM ET
    $SLDP
    Industrial Machinery/Components
    Miscellaneous

    Citigroup initiated coverage on Natera with a new price target

    Citigroup initiated coverage of Natera with a rating of Buy and set a new price target of $300.00

    1/7/26 9:12:45 AM ET
    $NTRA
    Medical Specialities
    Health Care

    $ADAG
    $BANL
    $DATS
    $ESLA
    SEC Filings

    View All

    SEC Form DEFA14A filed by Natera Inc.

    DEFA14A - Natera, Inc. (0001604821) (Filer)

    4/23/26 4:57:03 PM ET
    $NTRA
    Medical Specialities
    Health Care

    SEC Form DEF 14A filed by Natera Inc.

    DEF 14A - Natera, Inc. (0001604821) (Filer)

    4/23/26 4:44:24 PM ET
    $NTRA
    Medical Specialities
    Health Care

    SEC Form 6-K filed by CBL International Limited

    6-K - CBL International Ltd (0001914805) (Filer)

    4/22/26 8:00:15 AM ET
    $BANL
    Oil Refining/Marketing
    Energy

    $ADAG
    $BANL
    $DATS
    $ESLA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hanish Arnold C bought $3,740 worth of shares (5,000 units at $0.75) (SEC Form 4)

    4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)

    11/24/25 5:08:13 PM ET
    $SLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Exec VP Finance, CFO Rosenblum Mark J bought $16,000 worth of shares (20,000 units at $0.80), increasing direct ownership by 11,299% to 20,177 units (SEC Form 4)

    4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)

    11/20/25 4:42:09 PM ET
    $SLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Myman Darin M bought $4,392 worth of shares (2,000 units at $2.20), increasing direct ownership by 1% to 184,516 units (SEC Form 4)

    4 - Myseum, Inc. (0001648960) (Issuer)

    8/28/25 6:07:47 PM ET
    $DATS
    Telecommunications Equipment
    Telecommunications

    $ADAG
    $BANL
    $DATS
    $ESLA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Larry Elder Secures Fifth Radio Hall of Fame Nomination, Highlighting Decades of National Influence

    CAMARILLO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Salem Media (OTCQX:SALM) announced today that Salem Radio Network host Larry Elder has been nominated for induction into the Radio Hall of Fame, marking his fifth recognition by industry leaders for his career impact and audience reach. Elder, a New York Times bestselling author and host of the nationally syndicated Larry Elder Show, is heard weekdays from 3 to 6 p.m. Pacific Time on flagship station AM 870 The Answer, KRLA in Los Angeles, and across Salem Radio Network affiliates nationwide. Known as "The Sage from South Central," Elder has been a consistent voice in talk radio for more than 30 years, shaping national conversations on

    4/22/26 9:00:00 AM ET
    $SALM
    Broadcasting
    Consumer Discretionary

    Solid Power, Inc. Announces Timing of First Quarter 2026 Earnings Release and Conference Call

    Solid Power, Inc. (NASDAQ:SLDP), a leading developer of solid-state battery technology, today announced that it will release its first quarter 2026 results after market close on Tuesday, May 5, 2026, to be followed by a conference call at 2:30 p.m. MT (4:30 p.m. ET) on the same day. The call may be accessed through a live audio webcast on Solid Power's Investor Relations website at www.solidpowerbattery.com/investor-relations. An audio replay will be available at the same location. About Solid Power Solid Power is developing solid-state battery technology to enable the next generation of batteries for the fast-growing EV and other markets. Solid Power's core technology is its electrol

    4/21/26 4:05:00 PM ET
    $SLDP
    Industrial Machinery/Components
    Miscellaneous

    Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug's Potential as a Backbone Combination Therapy for Multiple Tumor Types

    Triple combination of muzastotug + atezolizumab + bevacizumab resulted in much higher overall response rates (ORR) compared to the atezolizumab + bevacizumab control arm (66.7% vs. 32.5%, respectively by Investigator per HCC-specific Modified RECIST v1.1) as 1L therapy in a Phase 1b/2 trial in locally advanced or metastatic and/or unresectable hepatocellular carcinoma (HCC) patients Triple combination of muzastotug + pembrolizumab + fruquintinib exhibited a dose-dependent response (25% and 40% ORR for 10 mg/kg and 15 mg/kg, respectively) in a Phase 1b/2 trial in late-line microsatellite stable colorectal cancer (MSS CRC) patients New data are further evidence that muzastotug's masking tech

    4/17/26 4:01:00 PM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAG
    $BANL
    $DATS
    $ESLA
    Leadership Updates

    Live Leadership Updates

    View All

    Townhall Media Announces Larry O'Connor as New Editor of Townhall.com

    WASHINGTON, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Townhall Media, a subsidiary of Salem Media Group (OTCQX:SALM), today announced the appointment of Larry O'Connor as Editor of Townhall.com, effective immediately. Larry O'Connor is a trusted conservative voice known for credibility, clarity, and consistency, earning the respect of audiences, peers, and industry leaders alike. He brings decades of experience across writing, podcasts, broadcast, and live events, along with a proven record of leadership, audience growth, and editorial excellence to one of the nation's most influential conservative platforms. O'Connor is known for his deep understanding of the political and cultural landscape. H

    1/20/26 9:15:00 AM ET
    $SALM
    Broadcasting
    Consumer Discretionary

    Octave Bioscience Expands Leadership Team with Appointment of Kirk Stockwood Senior Vice President, Commercial

    Octave Bioscience, Inc., a commercial stage precision medicine company pioneering biomarker driven solutions for multiple sclerosis, Parkinson's disease and other neurodegenerative diseases today announced the appointment of Kirk Stockwood as Senior Vice President, Commercial. Mr. Stockwood will spearhead Octave's commercial strategy as the company scales operations and expands the reach of its precision neurology platform. Mr. Stockwood brings over 20 years of leadership experience in specialty diagnostics and tools, with a proven track record of commercial scaling within public and private companies. Most recently as Vice President of Sales at Quanterix, he led a global team focused on

    1/8/26 4:01:00 PM ET
    $NTRA
    Medical Specialities
    Health Care

    Phunware Announces Appointment of Elliot Han as Chairperson of the Board of Directors

    Experienced Corporate Finance and Technology/Digital-Asset Leader to Guide Board Strategy and Growth Initiatives AUSTIN, Texas, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Phunware, Inc. ("Phunware" or the "Company") (NASDAQ:PHUN), the enterprise cloud platform for mobile that provides products, solutions, data, and services for brands to engage, manage and monetize global audiences, today announced that Elliot Han was appointed Chairperson of the Company's Board of Directors and Chairperson of the Board's Audit Committee, each effective October 2025. Mr. Han has served as a Class II non-employee Director on the Company's Board since January 2024 and will continue to chair the Board's Compensation

    12/2/25 8:31:00 AM ET
    $PHUN
    EDP Services
    Technology

    $ADAG
    $BANL
    $DATS
    $ESLA
    Financials

    Live finance-specific insights

    View All

    Solid Power, Inc. Announces Timing of First Quarter 2026 Earnings Release and Conference Call

    Solid Power, Inc. (NASDAQ:SLDP), a leading developer of solid-state battery technology, today announced that it will release its first quarter 2026 results after market close on Tuesday, May 5, 2026, to be followed by a conference call at 2:30 p.m. MT (4:30 p.m. ET) on the same day. The call may be accessed through a live audio webcast on Solid Power's Investor Relations website at www.solidpowerbattery.com/investor-relations. An audio replay will be available at the same location. About Solid Power Solid Power is developing solid-state battery technology to enable the next generation of batteries for the fast-growing EV and other markets. Solid Power's core technology is its electrol

    4/21/26 4:05:00 PM ET
    $SLDP
    Industrial Machinery/Components
    Miscellaneous

    Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics' MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma

    Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today highlighted Allogene Therapeutics' (NASDAQ:ALLO) interim futility analysis from its registrational ALPHA3 trial for cemacabtagene ansegedleucel (cema-cel), an investigational allogeneic anti-CD19 CAR T therapy, in first-line (1L) consolidation large B-cell lymphoma (LBCL). The ALPHA3 trial is enrolling patients with LBCL who test positive for molecular residual disease (MRD) following 1L therapy. These patients are then randomized either to cema-cel, an investigational allogeneic anti-CD19 CAR T therapy developed by Allogene, or observation. The interim analysis showed that 58.3% of MRD-positive pat

    4/13/26 8:00:00 AM ET
    $ALLO
    $NTRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical Specialities

    Rail Vision Announces Second Half and Full Year 2025 Financial Results

    Company presents strong balance sheet with year-end cash of approximately $20 million and zero debt Revenue up 14.4% year-over-year Ra'anana, Israel, March 31, 2026 (GLOBE NEWSWIRE) -- Rail Vision Ltd. (NASDAQ:RVSN, FSE: C80)) ("Rail Vision" or the "Company"), an early commercialization stage technology company transforming railway safety through advanced AI-integrated sensing systems, today announced its financial results for the second half and full year ended December 31, 2025. The Company reported revenue growth and operational progress, strengthening its global market presence. "2025 was a transformative year for Rail Vision," said David BenDavid, Chief Executive Officer. "We advan

    3/31/26 4:02:00 PM ET
    $RVSN
    Railroads
    Industrials

    $ADAG
    $BANL
    $DATS
    $ESLA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by LQR House Inc.

    SC 13D/A - LQR House Inc. (0001843165) (Subject)

    11/25/24 4:41:10 PM ET
    $LQR
    Beverages (Production/Distribution)
    Consumer Staples

    Amendment: SEC Form SC 13G/A filed by Verb Technology Company Inc.

    SC 13G/A - Verb Technology Company, Inc. (0001566610) (Subject)

    11/15/24 8:24:57 PM ET
    $VERB
    Other Consumer Services
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Salarius Pharmaceuticals Inc.

    SC 13G/A - Salarius Pharmaceuticals, Inc. (0001615219) (Subject)

    11/14/24 4:38:31 PM ET
    $SLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care